leadf
logo-loader
viewXPhyto Therapeutics Corp.
(
CSE:XPHYOTCQB:XPHYF
)

XPhyto German subsidiary Vektor Pharma builds oral disintegrating film formulation for big European client

In the third quarter, Vektor completed manufacturing ODF clinical trial materials, which will now be delivered for clinical evaluation

DNA graphic next to microscope
The ODF technology is designed to quickly adjust to various active pharmaceutical ingredients to deliver dosage that matches the client’s needs

XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) announced Monday that its German subsidiary Vektor Pharma TF GmbH has developed an oral disintegrating film (ODF) drug delivery mechanism for a major European generic drug company. 

During the third quarter, Vektor completed manufacturing ODF clinical trial materials, which the company says will now be delivered for clinical evaluation.

The ODF technology is designed to quickly adjust to various active pharmaceutical ingredients (APIs) in order to deliver dosage that matches the client’s needs. The film works by dissolving on the tongue. 

READ: XPhyto Therapeutics provides update on its oral disintegrating film (ODF) drug delivery programs

"Our ODF drug delivery platform provides a fast-track opportunity to bring new drug formulations to market," Vektor Managing Director Thomas Beckert said in a statement. "XPhyto is developing a pipeline of new dosage formulations based on approved APIs but Vektor is also working for drug companies as a development and manufacturing partner. Vektor can provide its clients with a versatile and rapidly adjustable ODF and transdermal dosage platform to create new delivery options for generic and non-generic APIs."

Vektor has worked extensively for major and emerging drug companies to develop new and innovative dosage formulations based on its ODF and transdermal drug delivery platforms, the company said. Its contract work has included generic dosage formulations for Fentanyl, Rivastigmine, Clonidine, and Rotigotine, as well as novel non-generic active formulations for the treatment of Parkinson's disease, restless leg syndrome, incontinence, local pain and abuse-resistant pain medications.

In other news, the company said it plans to provide an update on its saliva-based COVID-19 screening test development program and additional related news shortly.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: XPhyto Therapeutics Corp.

Follow
CSE:XPHY

Price: 1.4 CAD

Market Cap: $97.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics takes a major step forward launching first commercial...

XPhyto Therapeutics CEO Hugh Rogers joined Steve Darling from Proactive to share details the company and their partner 3a-diagnostics have successfully registered their first biosensor test in oral inflammation with the German authorities. Rogers telling Proactive this will be an at-home...

3 weeks, 2 days ago

2 min read